Market closed
Celularity/$CELU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celularity
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.
Ticker
$CELU
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
120
Website
Celularity Metrics
BasicAdvanced
$38M
-
-$1.66
0.61
-
Price and volume
Market cap
$38M
Beta
0.61
52-week high
$3.82
52-week low
$1.00
Average daily volume
48K
Financial strength
Current ratio
0.19
Quick ratio
0.117
Long term debt to equity
153.073
Total debt to equity
399.659
Interest coverage (TTM)
-7.81%
Management effectiveness
Return on assets (TTM)
-17.45%
Return on equity (TTM)
-147.50%
Valuation
Price to revenue (TTM)
0.732
Price to book
2.12
Price to tangible book (TTM)
118.82
Price to free cash flow (TTM)
-2.708
Growth
Revenue change (TTM)
225.94%
Earnings per share change (TTM)
-84.79%
3-year revenue growth (CAGR)
34.70%
3-year earnings per share growth (CAGR)
-58.17%
What the Analysts think about Celularity
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Celularity stock.
Celularity Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Celularity Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Celularity News
AllArticlesVideos
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
GlobeNewsWire·2 weeks ago
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
GlobeNewsWire·4 weeks ago
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Celularity stock?
Celularity (CELU) has a market cap of $38M as of May 09, 2025.
What is the P/E ratio for Celularity stock?
The price to earnings (P/E) ratio for Celularity (CELU) stock is 0 as of May 09, 2025.
Does Celularity stock pay dividends?
No, Celularity (CELU) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Celularity dividend payment date?
Celularity (CELU) stock does not pay dividends to its shareholders.
What is the beta indicator for Celularity?
Celularity (CELU) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.